In consultation with Health Canada, four companies (Cobalt Pharmaceuticals, Laboratoire Riva, Mylan Pharmaceuticals and Sanis Health) are voluntarily recalling various lots of five prescription drugs (amlodipine, ciprofloxacin, lamotrigine, norfloxacin and telmisartan) from the Canadian market (see chart below). The voluntary recall is a precautionary measure due to quality concerns at the manufacturing facility of the active ingredients used in the products. The issues are primarily around processes that affect quality control and oversight.

To read the full article, click here.

Website Designed and Hosted by The Social Business